Prednisone acetate
Phase 2Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Prednisone acetate is one of 83 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 2.
3
Indications
9
Total Trials
3
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Fluciclovine
UUniversity of Utah
Phase 3
Fuzuloparib
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
Prednisone acetate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
Metastatic Prostate Cancer2 trials
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04992026·130 enrolled
Henoch-Schönlein Purpura1 trial
1 more indication
Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prednisone acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details